|
|||||
|
|
Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab |
|
| Authors: | Dawn Odom Beth Barber Lee Bennett Marc Peeters Zhongyun Zhao James Kaye Michael Wolf Jeffrey Wiezorek |
| Affiliation: | (1) RTI Health Solutions, 3040 East Cornwallis Road, Post Office Box 12194, Research Triangle Park, NC 22709-2194, USA;(2) Amgen Inc, One Amgen Center Drive, Thousand Oaks, CA 91320-1799, USA;(3) University Hospital Antwerp, Wilrijkstraat 10, B-2650, Edegem, Antwerp, Belgium; |
| Abstract: | PurposePanitumumab monotherapy is approved for chemotherapy-refractory wild-type KRAS metastatic colorectal cancer (mCRC). Patient-reported outcomes—although important in the palliative setting—have not been reported in this patient population. |
| Keywords: | |
| 本文献已被 PubMed SpringerLink 等数据库收录！ | |